Humacao, Puerto Rico Saturday, April 12, 2025, 11:00 Hrs [IST] ...

Aspire Biopharma (ASBP) announced initiation of its Phase 1 single- center clinical study of its lead therapeutic candidate, an oral ...

However, they can also be dangerous. Usually, painkillers contain a mixture of paracetamol, aspirin, and caffeine. Sometimes powdered products absorb faster than pills or capsules. However ...

Aspire's lead product candidate, high-dose sublingual aspirin, is a granular or powder formulation of a soluble, Ph neutral, fast-acting aspirin designed to address cardiology emergencies and pain ...

Phase 1 Study Design The objectives of this Phase 1 single dose clinical study are to evaluate the safety, pharmacokinetics and pharmacodynamics of Aspire's sublingual aspirin powder when administered ...

Phase 1 Study DesignThe objectives of this Phase 1 single dose clinical study are to evaluate the safety, pharmacokinetics and pharmacodynamics of Aspire's sublingual aspirin powder when ...